• Meilleur, an overseas affiliate, and its next-generation Aβ-PET imaging agent NAV-4694 for Alzheimer’s disease, have been acquired by the Nasdaq-listed company Lantheus.
• Jiangsu Sinotau Pharmaceutical Co., Ltd., a subsidiary, has obtained a radioactive drug business license.
• Sichuan Sinotau Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the Radiation Safety License.
• Sinotau is awarded the national “Specialized, Refined, and New ‘Little Giant’” enterprise title, highlighting our innovation capabilities and market competitiveness.